Future and ongoing studies will show how long HBIg must be given

Future and ongoing studies will show how long HBIg must be given after transplantation, especially when used in combination with potent antivirals, such as entecavir or tenofovir.”
“Introduction: Preclinical assessment of the heart rate corrected QT interval (QTc)

is an important component of the cardiovascular safety evaluation in drug discovery. Here we aimed to quantify the translational relationship between QTc prolongation and shortening in the conscious telemetered dog and humans by a retrospective pharmacokinetic-pharmacodynamic (PKPD) analysis. Methods: QTc effects of 2 proprietary compounds and 2 reference drugs (moxifloxacin and dofetilide) were quantified in conscious dogs and healthy volunteers via a linear and Emax pharmacokinetic-pharmacodynamic models. The translational relationship was quantified by correlating the QTc response from GW4869 manufacturer dog and human at matching free drug concentrations. Results: A consistent translational relationship was found at low delta-QTc intervals indicating that a QTc change of 2.5-8 ms in dog would correspond to a 10 ms change in human. Discussion: The translational relationship developed here can be used to predict the QTc liability in human using preclinical dog data. It could

therefore help protect the health of human volunteers, for example by appropriate clinical study design and dose selection, as well as improve future decision-making and help reduce compound attrition due to changes in QT interval. (C) 2013 Elsevier Inc. All rights reserved.”
“OBJECTIVES: DMXAA ic50 Left ventricular (LV) hypertrophy in aortic stenosis (AS) is considered a compensatory response helping maintain systolic function, but constitutes a risk factor for cardiac morbidity and mortality. The aim of this study was to assess the degree of LV mass regression after sutureless implantation of the Perceval S aortic valve bioprosthesis (Sorin Group, Saluggia, Italy).

METHODS: Between March 2010 and July 2012, 78 patients

with symptomatic AS underwent isolated aortic valve replacement (AVR) with the Perceval bioprosthesis. Mean age was 77.1 +/- 5.3 years, 46 patients were buy FDA-approved Drug Library female (59%) and mean logistic EuroSCORE was 11 +/- 7.5%. Echocardiography was performed preoperatively, at discharge, and at follow-up (mean 13.5 +/- 7.3 months). LV mass was calculated using the Devereux formula and indexed to body surface area.

RESULTS: There was 1 in-hospital non-cardiac death and 3 late deaths. LV mass index decreased from 148.4 +/- 46 g/m(2) at baseline to 119.7 +/- 38.5 g/m(2) at follow-up (P = 0.002). No significant changes were observed in LV hypertrophy and/or relative wall thickness >0.42 as well as in LV ejection fraction. Mean aortic gradient decreased from 49.5 +/- 15.8 mmHg at baseline to 11.6 +/- 5.1 mmHg at discharge and 8.3 +/- 4.4 mmHg at follow-up (P < 0.001), resulting in significant clinical improvement.

Comments are closed.